WHO ICTRP trial
Bioequivalence study of Telmisartan 80 mg tablet in 24 healthy male under…
IRCT20180620040164N89 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20180620040164N89 |
|---|---|
| Public title | Bioequivalence study of Telmisartan 80 mg tablet in 24 healthy male under fasting conditions |
| Scientific title | Comparative bioequivalence study of Telmisartan 80 mg tablet of ActoverCo. and ®Micardis of Boehringer Ingelheim in 24 healthy male under fasting. |
| Primary sponsor | Actoverco. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Essential (primary) hypertension. Essential (primary) hypertension |
| Interventions | Intervention 1: Intervention group: Telmisartan 80 mg, produced by ActoverCo. is the test product. In each period, 12 of 24 subjects will be given a single oral dose of this product. Intervention 2: Intervention group: Micardis® 80 mg… |
| Registration date | May 14, 2025 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: